SURGE Therapeutics

SURGE Therapeutics is a biotechnology startup founded in 2016 and based in the United States. The company's mission is to revolutionize cancer immunotherapy by focusing 100% of the effective dose at the right place and time to significantly enhance patient survival rates. With the slogan "The intraoperative immunotherapy company," SURGE is dedicated to preventing post-surgical cancer recurrence, addressing a critical need in cancer treatment. Recently, the company received a substantial $32.00M Series B investment on 19 July 2023, with contributions from prominent investors including Khosla Ventures, Pitango Venture Capital, DHVC, Alumni Ventures Blockchain Fund, Camford Capital, Cancer Research Institute, Green D Ventures, Intuitive, Piedmont Capital, and Castor Ventures.

Moreover, by leveraging cutting-edge technology and a deep understanding of the biotechnology and healthcare industries, SURGE is poised to disrupt the current treatment landscape for solid tumors. The company's innovative approach and strong investor support position it as a compelling player in the rapidly evolving field of cancer therapeutics. With a focus on efficacy, precision, and patient outcomes, SURGE Therapeutics is a promising venture with the potential to make a significant impact on cancer care.